Patients with pulmonary hypertension related to congenital systemic-to-pulmonary shunts are characterized by inflammation involving endothelial cell activation and platelet-mediated inflammation

Congenital Heart Disease

Volumn 4, Issue 3, 2009, Pages 153-159

  Brun, Henrik ^a   Holmstrøm, Henrik ^a   Thaulow, Erik ^a   Damås, Jan Kristian ^a   Yndestad, Arne ^a   Aukrust, Pål ^a   Ueland, Thor ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Congenital heart defects; Inflammation; Pulmonary hypertension

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; C REACTIVE PROTEIN; CD40 LIGAND; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD SAMPLING; CELL ACTIVATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYANOSIS; DOWN SYNDROME; DRUG RESPONSE; EISENMENGER COMPLEX; ENDOTHELIUM CELL; ENZYME IMMUNOASSAY; FEMALE; HEART CATHETERIZATION; HUMAN; LUNG VASCULAR RESISTANCE; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTEMIC PULMONARY SHUNT; THROMBOCYTE;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; CORONARY CIRCULATION; DOWN SYNDROME; ENDOTHELIAL CELLS; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; PULMONARY CIRCULATION; SULFONAMIDES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 66649137106     PISSN: 1747079X     EISSN: 17470803     Source Type: Journal    
DOI: 10.1111/j.1747-0803.2009.00297.x     Document Type: Article

References (21)

1. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease-long-term follow-up and prediction of outcome after surgical correction. Circulation. 1987;76:1037-1042.
2. Webb G, Gatzoulis MA. Atrial septal defects in the adult: Recent progress and overview. Circulation. 2006;114:1645-1653.
3. Caramuru LH, Lopes AA, Maeda NY, Aiello VD, Filho CC. Long-term behavior of endothelial and coagulation markers in Eisenmenger syndrome. Clin Appl Thromb Hemost. 2006;12:175-183.
4. De PSS, Maeda NY, Bydlowski SP, Lopes AA. Markers of endothelial dysfunction and severity of hypoxaemia in the Eisenmenger syndrome. Cardiol Young. 2005;15:504-513.
5. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994;144:275-285.
6. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J. 2003;22:358-363.
7. Kimura H, Okada O, Tanabe N, et al. Plasma monocyte chemoattractant protein-1 and pulmonary vascular resistance in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2001;164:319-324.
8. Brun H, Thaulow E, Fredriksen PM, Holmstrom H. Treatment of patients with Eisenmenger's syndrome with bosentan. Cardiol Young. 2007;17:288-294.
9. Bowyer JJ, Busst CM, Denison DM, Shinebourne EA. Effect of long-term oxygen treatment at home in children with pulmonary vascular disease. Br Heart J. 1986;55:385-390.
10. Bollerslev J, Ueland T, Jorgensen AP, et al. Positive effects of a physiological dose of GH on markers of atherogenesis: A placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol. 2006;154:537-543.
11. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007-2011.
12. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
13. Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol. 1998;18:1386-1392.
14. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation. 1958;18:533-547.
15. Caramuru LH, Soares RP, Maeda NY, Lopes AA. Hypoxia and altered platelet behavior influence von Willebrand factor multimeric composition in secondary pulmonary hypertension. Clin Appl Thromb Hemost. 2003;9:251-258.
16. Rabinovitch M, Andrew M, Thom H, et al. Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation. 1987;76:1043-1052.
17. Damas JK, Otterdal K, Yndestad A, et al. Soluble CD40 ligand in pulmonary arterial hypertension: Possible pathogenic role of the interaction between platelets and endothelial cells. Circulation. 2004;110:999-1005.
18. Lawrie A, Waterman E, Southwood M, et al. Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension. Am J Pathol. 2007;172:256-264.
19. Perloff JK, Hart EM, Greaves SM, Miner PD, Child JS. Proximal pulmonary arterial and intrapulmonary radiologic features of Eisenmenger syndrome and primary pulmonary hypertension. Am J Cardiol. 2003;92:182-187.
20. Friedman R, Mears JG, Barst RJ. Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension. Circulation. 1997;96:2782-2784.
21. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, et al. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2006;291:L668-L676.